Internal Medicine is a distinguished peer-reviewed journal published by the Japan Society of Internal Medicine, focusing on the nuanced field of internal medicine. Since its inception in 1974 and with a commitment to advancing medical knowledge, the journal has evolved remarkably, aiming to disseminate high-quality research that contributes to the understanding and treatment of internal diseases. Operating from Tokyo, Japan, it provides an intellectual platform for researchers and clinicians to publish original articles, reviews, and case studies that address various aspects of internal medicine. The journal currently holds a ranking in the Q3 quartile for both Internal Medicine and miscellaneous Medicine categories as of 2023, signifying its growing influence in the medical community. Although not an open-access journal, it remains accessible to a wide audience through institutional subscriptions, enhancing its reach among professionals and students alike. With its commitment to excellence, Internal Medicine serves as an essential resource for those seeking the latest developments and research within this vital medical field.

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

The Revista Espanola de Quimioterapia, published by the SOCIEDAD ESPANOLA QUIMIOTERAPIA, is a pivotal open-access journal that has been advancing the field of clinical microbiology and pharmacology since its inception in 1989. With an E-ISSN of 1988-9518, this journal caters to a diverse audience of researchers, healthcare professionals, and students, providing them with critical insights into the latest developments in medicinal chemistry and therapeutic strategies. Located in Madrid, Spain, the journal reflects the rigorous academic standards of its associated institutions, contributing significantly to the translation of research into clinical practice. Achieving a Q3 ranking in the fields of Medicine, Microbiology, and Pharmacology in 2023 attests to its growing influence and relevance in the scientific community, making it a vital resource for those engaged in the quest for innovative solutions to pressing healthcare challenges. The journal prides itself on its commitment to maintaining an open-access model since 2018, ensuring that vital research is freely accessible to foster greater knowledge sharing and collaboration within the global scientific community.

Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

The Journal of Ophthalmic Inflammation and Infection, published by SPRINGER since 2011, stands as a pivotal resource for professionals in the fields of ophthalmology and infectious diseases. With an impactful Q2 ranking in both categories as of 2023, this open access journal is dedicated to disseminating high-quality research and reviews related to ocular inflammation and its infectious causes, fostering a deeper understanding of these critical health issues. The journal is well-regarded in the academic community, currently positioned at Rank #43 in Ophthalmology, reflecting its significance and influence within the discipline. The journal is accessible globally from its base in Germany, offering valuable insights to researchers, healthcare professionals, and students alike. With a commitment to excellence in publishing through 2024 and beyond, this journal continues to contribute meaningfully to innovative studies and clinical practices in ocular health.

LANCET INFECTIOUS DISEASES is a premier journal published by Elsevier Science Ltd, dedicated to disseminating high-quality research and comprehensive reviews in the field of infectious diseases. Since its inception in 2001, the journal has become a pivotal resource in the medical community, recognized for its rigorous peer-review process and impactful contributions to public health. With an impressive Scopus rank of #2 out of 344 in the category of Medicine - Infectious Diseases, it consistently ranks in the 99th percentile, highlighting its importance and influence in shaping clinical and epidemiological research. The journal's commitment to advancing knowledge in infectious diseases is underscored by its Q1 quartile designation in 2023, affirming its status as a leading academic outlet. Although not an open-access journal, LANCET INFECTIOUS DISEASES provides essential insights for researchers, healthcare professionals, and students, bridging the gap between cutting-edge research and practical application in an increasingly interconnected world.

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

CLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.